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Abstract Phosphorylation on tyrosine residues is a key step in signal transduction pathways mediated by membrane proteins. Although it is known 
that human breast cancer tissue expresses at least 2 MUCl type 1 membrane proteins (a polymorphic high molecular weight MUCl glycoprotein 
that contains a variable number of tandem 20 amino acid repeat units, and the MUClN protein that is not polymorphic and is lacking this repeat 
array) their function in the development of human breast cancer has remained elusive. Here it is shown that these MUCl proteins are extensively 
phosphorylated, that phosphorylation occurs primarily on tyrosine residues and that following phosphorylation the MUCl proteins may potentially 
interact with SH2 domain-containing proteins and thereby initiate a signal transduction cascade. As with cytokine receptors, the MUCl proteins 
do not harbor intrinsic tyrosine kinase activity yet are tyrosine phosphorylated and the MUClN protein participates in a cell surface heteromeric 
complex whose formation is mediated by two cytoplasmically located MUCl cysteine residues. Furthermore, the MUClN protein demonstrates 
sequence similarity with sequences present in cytokine receptors that are known to be involved in ligand binding. Our results demonstrate that the 
two MUCl isofotms are both likely to function in signal transduction pathways and to be intimately linked to the oncogenetic process and suggest 
that the MUClN protein may act in a similar fashion to cytokine receptors. 
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1. lntroductlon 
Protein products of the MUCl gene are expressed at high 
levels in adenocarcinomas and especially in human breast can- 
cer tissue [l-7] and disease status in breast cancer patients is 
routinely assessed by monitoring the serum levels of circulating 
MUCl proteins (variously referred to as episialin, H23Ag, 
ETA - epithelial tumor antigen, PEM - polymorphic epithelial 
mucin, EMA - epithelial membrane antigen, CA15-3, MCA - 
mammary carcinoma antigen, etc.). Molecular studies, includ- 
ing cDNA and gene cloning [8-141, have elucidated many prop- 
erties of the MUCl proteins. One of the MUCl gene products 
is a polymorphic type 1 transmembrane molecule that consists 
of a large extracellular domain, a transmembrane domain and 
a 72 amino acid cytoplasmic tail (Fig. 1 F, upper molecule). The 
genetic polymorphism derives from a tandem array of variable 
numbers of a highly conserved 20 amino acid repeat motif 
present within the extracellular domain. Soon after translation 
and prior to its translocation to the cell surface, this MUCl 
protein (designated MUCVREP) undergoes proteolytic cleav- 
age in a region that is located 45 to 60 amino acids N-terminal 
to the transmembrane domain [15]. The two resulting protein 
molecules form a tight heterodimer complex that is composed 
of the large extracellular domain linked by non-covalent, SDS 
sensitive bonds to the much smaller (20-30 kDa) protein mole- 
cule containing the cytoplasmic and transmembrane domains 
[15]. Expression of the MUCl/REP protein in cell transfectants 
reduces cellular aggregation that is mediated by the highly 
glycosylated tandem repeat domain [16]. 
An additional novel MUCl protein (designated MUCl/Y) 
has been recently characterized [8] that is devoid of the hall- 
mark feature of MUCl, the tandem repeat array, yet retains the 
MUCl N-terminal, transmembrane and cytoplasmic domains 
(Fig. lF, lower molecule). The MUCIN protein is generated 
by a splicing mechanism that utilizes perfect alternative splice 
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donor and splice acceptor sites located upstream and down- 
stream to the tandem repeat array. Previous work demon- 
strated that the mature MUClN protein has a molecular mass 
of between 4245 kDa indicating that, in contrast to the cleaved 
MUCl/REP, it does not undergo proteolytic cleavage and is 
therefore continuous from its N-terminal extracellular domain 
through to its C-terminal cytoplasmic domain. In addition to 
the mature 4245 kDa MUClN protein, a precursor 33 kDa 
MUClN protein that subsequently undergoes post-transla- 
tional glycosylation modifications was also identified [8]. Signif- 
icantly, both the MUCVREP and MUClN isoforms are 
highly expressed in human breast cancer tissue [l-8]. 
As the MUCl/REP and the novel MUClN proteins are 
anchored at the cell surface and contain extracellular and com- 
mon transmembrane and cytoplasmic domains they may both 
be involved in signal transduction processes. 
Membrane proteins participating in signal transduction 
processes are in many cases modifled by phosphorylation. It 
has not been known whether the MUCl proteins are at all 
phosphorylated - indeed the MUCl cytoplasmic domain does 
not contain any conserved sequence motifs known to exist in 
the catalytic domains of kinases in general or tyrosine kinases 
in particular, and is thus devoid of endogenous kinase activity 
and cannot undergo autophosphorylation. Similarly, cytokine 
receptors are also devoid of intrinsic kinase activity but are in 
many instances transphosphorylated on tyrosine residues by 
cytoplasmic tyrosine kinases [17-211. It is shown here, for the 
first time, that the MUCI proteins are phosphorylated on tyro- 
sine residues and that following phosphorylation they have the 
potential to interact with SH2 domain containing proteins and 
thereby initiate a signal transduction cascade. Furthermore we 
show that, as with cytokine receptors, the MUClN isoform 
participates in a cell-surface heteromeric complex. Interest- 
ingly, the MUClN protein demonstrates sequence similarity 
with sequences present in cytokine receptors that are known to 
be involved in ligand binding. Our results demonstrate that the 
two MUCl isoforms are both likely to function in signal 
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transduction pathways and to be intimately linked to the onco- 
genetic process and suggest hat the MUClN protein may act 
in a similar fashion to cytokine receptors. 
2. Materials and methods 
2.1. Cells 
Stable transfectants were generated by co-transfccting an expression 
nlasmid harbor&z either MUCl/REP or MUClN cDNA with the 
neomycin plasmid @SV2 neo) selection marker into HBLlOO human 
mammary epithelial cells (MUCl/REP transfectants) or into 3T3 ras 
transformed fibroblasts (MUClN transfectants). These cells were cho- 
sen as they showed the highest expression levels of the respective MUCl 
isoforms. Transient ransf&ants were prepared using the T7/ encepha- 
lomyocarditis virus/vaccinia sysytem (described below) and the monkey 
epithelial cell line, BSC-1. 
2.2. cDNA constructs 
The generation of expression vectors harboring either the full-length 
transmembrane MUCl/REP or the novel MUClN cDNA and driven 
by the HMG coenzyme A reductase promoter (expression vector 
pCL642) has been previously described [8]. 
2.3. Transient expression of the novel MUCI protein in the T7lEMCI 
vaccinia system 
Transient expression of the novel MUClN protein synthesized in a 
state as close as possible to the naturally occurring MUCIN protein, 
was accomplished using the T7tEMUvaccinia hybrid expression sys- 
tem [8]. This system utilizes the bacteriophage T7 RNA polymerase 
which is encoded by a recombinant vaccinia virus to transcribe genes 
that are regulated by the T7 promoter in the cytoplasm of infected 
mammalian cells. The MUClN cDNA was inserted into the DTM~ 
vector under the control of the T7 promoter and EMCV leader, and 
introduced into tissue cultured BSC-1 epithelial cells together with 
recombinant vaccinia virus which expresses T7 RNA polymerase [8]. 
2.4. Western blot analyses 
Cell lysates were prepared by adding lysis buffer (50 mM NaCl, 20 
mM Tris-HCI, pH 7.4, lOO~g/ml leupeptin and 0.5% Nonidet P-40) to 
cell pellets, followed by vortex mixing and sonic&ion (3 times 10 second 
bursts using a Branson sonicator). Cell debris was removed by centrif- 
ugation at 10,000 rpm for 10 min. All procedures were performed at 
4OC or on ice. Protein samples were denatured by boiling in SDS buffer 
containing mercaptoethanol and analymd on SDS/acrylamide g ls. The gel 
was electrotransferred for 3 h at 1 A to nitrocellulose filters that were 
then blocked in PBS containing 5% skimmed milk followed by incuba- 
tion with the primary antibody. The filters were washed in PBS and then 
incubated with a secondary anti-rabbit (or anti-mouse antibody) conjugated 
to horseradish peroxidase followed by ECL (Amersham) detection. 
2.5. Antibodies 
Western blot analyses were performed with a polyclonal antibody (a 
kind gift from Dr. Sandra Gendler) directed against the oligopeptide 
SSLSYTNPAVAATSANL (amino acids 499 to 515, see [8] for amino 
acid numbering) which represents the C-terminal region of the MUCl 
cytoplasmic domain. The polyclonal antibody was precleared by ad- 
sorption against glutaraldehyde insolubihxed human serum. 
2.6. Metabolic labelling of cells with phosphate 
Cells were incubated overnight in low phosphate medium supple- 
mented with 10% fetal calf serum that had been dialyzed against saline. 
The following day radioactive carrier-free inorganic phosphate was 
added to the cells and incubation continued for another 8 h. Thirty 
minutes prior to harvesting, the cells were treated with the tyrosine 
phosphatase inhibitors, sodium vanadate (200 PM) and hydrogen per- 
oxide (200 PM). 
2.7. Immunoprecipitations 
Cell lysates prepared as described above were added to protein-A- 
agarose-antibody complexes and incubated for 2 h at 4°C. The im- 
munocomplex was washed 3 times with cell lysis buffer and 2 x SDS 
sample buffer was added. 
3. Results and discussion 
To investigate whether MUCl is transphosphorylated, stable 
transfectants expressing either the MUCllREP protein or the 
novel MUClN protein were generated. Immunoblotting 
experiments with antibodies directed against the MUCl cyto- 
plasmic domain confirmed MUCWREP (2&30 kDa im- 
munoreactive proteins) and MUClN (4245 kDa im- 
munoreactive proteins) expression in the respective transfec- 
tams (Fig. 1A). MUCl expressing transfectants were incubated 
with radioactively labelled inorganic phosphate in the presence 
of the tyrosine phosphatase inhibitors, hydrogen peroxide and 
sodium vanadate [22,23], cell lysates were then prepared and 
subjected to immunoprecipitation with anticytoplasmic domain 
antibodies. The specifically immunoprecipitated proteins mi- 
grating with molecular masses of 20-30 kDa for the MUCl/ 
REP protein (Fig. lB, lane 2) and 42-45 kDa for the MUClN 
protein (Fig. lB, lane 6) were highly labelled, indicating that the 
MUCl proteins had undergone extensive phosphorylation. 
Similarly the MUCl proteins were also found to be 
phosphorylated in non-transfected human T47D breast cancer 
cells (data not shown). Due however to the considerably lower 
level of expression as compared to that in the MUCl transfec- 
tants, the signal of the phosphorylated MUCl proteins in the 
T47D cells was correspondingly lower and further work was 
thus conducted with the MUCI transfectants. 
The effect of the tyrosine phosphatase inhibitors on the levels 
of MUCl phosphorylation was next investigated. In the ab- 
sence of these inhibitors, MUCl phosphorylation demon- 
strated a low yet sigticant level of phosphorylation that in 
their presence was markedly enhanced (Fig. lC,D) suggesting 
that phosphorylation of the MUCl proteins occurs predomi- 
nantly on tyrosine residues. Consistent with this, nonspecifi- 
cally precipitated labelled proteins (Fig. lC, open arrow at left 
of figure) showed no differential enhancement of phosphoryla- 
tion following treatment of cells with the tyrosine phosphatase 
inhibitors. 
A phosphoamino acid analysis performed on the labelled 
phosphorylated MUCl proteins showed that phosphorylation 
had indeed primarily occurred on tyrosine residues (70-90% in 
different experiments), with much reduced levels of phosphos- 
erine and undetectable levels of threonine phosphorylation 
(Fig. 1E (a)). This pattern of tyrosine phosphorylation was 
observed both for the MUCl/REP and MUClN proteins. 
Further confirmation for tyrosine phosphorylation of the 
MUCl proteins was obtained by probing immunoblots of im- 
munoprecipitated MUCl proteins with antiphosphotyrosine 
antibodies. This analysis (Fig. 1E (b)) clearly showed that the 
MUClN protein is readily detected by antiphosphotyrosine 
antibodies following treatment of cells with tyrosine phosphat- 
ase inhibitors. 
Three independent lines of evidence thus support the finding 
that the MUCl proteins are phosphorylated on tyrosine res- 
idues: (i) increased levels of MUCl phosphorylation follow- 
ing treatment of cells with tyrosine phosphatase inhibitors, 
(ii) a phosphoaminoacid analysis of the MUCl proteins, 
and (iii) reactivity of phosphorylated MUCl proteins with an- 
tiphosphotyrosine antibodies. 
Interestingly, tyrosine residues are distributed in a markedly 
biased fashion within the MUCl proteins - 7 out of 72 of the 
amino acids comprising the MUCl cytoplasmic domain are 
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Fig. 1. Phosphorylation of the MUCl proteins on phosphotyrosine residues. (A) MUCl/REP and MUClN expression in stable transfectants. Cell 
lysates were prepared from the MUCllREP (lane 1) and MUClN transfectants (lane 2) and the proteins resolved on SDSpolyacrylamide (10%) 
gels, transferred to nitrocellulose and probed with polyclonal antisera directed against the MUCl cytoplasmic domain, as described in section 2. 
Molecular size standards (in kilodaltons) are shown at left. (R) Phosphorylation of the MUCl proteins. The MUCVREP transfectants (lanes 1 and 
2, MUCVREP), control neomycin transfected ras 3T3 fibroblasts (lanes 3 and 4, neo) and MUClN ras 3T3 fibroblast transfectants (lanes 5 and 
6, MUCl/Y) were labelled with radioactive carrier-free inorganic phosphate (section 2). The cells were then harvested, briefly washed with 
phosphate-buffered saline and cell lysates prepared that were then subjected to immunoprecipitation with either preimmune rabbit serum @IRS, lanes 
I,3 and 5) or anticytoplasmic domain antisera (IMM, lanes 2,4 and 6). Precipitated proteins were resolved on SDS-polyacrylamide (10%) gels and 
visual&d by autoradiography. (C) and (D) Effect of tyrosine phosphatase inhibitors on MUCl/REP (C) and MUClN (D) phosphorylation. 
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Fig. 2. The MUClN protein appears in a cell surface complex, the 
formation of which is mediated via MUCl cytoplasmic domain cysteine 
residues. Cell lysates were prepared from monkey BSC-lcells infected 
with recombinant vaccinia virus coding for T7 RNA polymerase and 
transfected with the pTM1 vaccinia expression vector harboring cDNA 
coding for either wild type MUClN protein (wt, lanes 2, 3, 5 and 6) 
or mutant MUClN protein (mut, lanes 1 and 4) in which the Cys-Gln- 
Cys (CQC) sequence had been mutated to Gly-Gin-Gly (see Fig. 1F for 
the location of the CQC sequence). The cell lysate proteins were re- 
solved on SDS polyacrylamide (10%) gels under non-reducing (- re- 
duct., lanes 4-6) or reducing (+ reduct., lanes l-3) conditions, trans- 
ferred to nitrocellulose and probed with polyclonal antisera directed 
against he MUCl cytoplasmic domain. Proteins resolved in lanes 3 and 
6 were derived from cells that prior to harvesting had been treated for 
15 min with 15 mM EDAC crosslinking agent (obtained from Sigma). 
Detection of bound antibodies was performed as described in Fig. IA. 
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tyrosine residues (Fig. 1F). The transmembrane domain con- 
tains one tyrosine residue and a further 5 tyrosine residues 
appear within the 92 amino acids N-terminally adjacent to the 
transmembrane domain - no additional tyrosine residues 
appear within the MUCI proteins. The MLJCl amino acid 
sequence also reveals a marked similarity between tyrosine 
containing sequences located within the MUCl cytoplasmic 
domain and phosphotyrosine containing peptide sequences 
that are postulated to speci&dly interact with SH2 domain 
containing proteins [26]. It should be emphasized that these 
sites represent only presumptive docking sites for SH2 domain 
containing proteins; it is nonetheless triking that the 72 amino 
acid MUCl cytoplasmic domain contains no less than 3 such 
possible sites. For example, the most preferred sequence for 
interaction with phospholipase C y 1 is pTyr-Val-Iso-Pro 
(pYVIP) and a very similar sequence [Tyr-Val-Pro-Pro 
(YVPP)] appears in the cytoplasmic domain of the MUCl 
protein. Additionally the sequence pTyr-Glu-Glu-Val 
(pYEEV) which is identical to a sequence. that appears within 
the mouse MUCl cytoplasmic domain, has been shown to be 
one of the most preferred sequences for interaction with a 
number of SH2 domain containing cytoplasmic tyrosine ki- 
nases [26] and a potential GRB-2 binding site (pYXNX) also 
appears in the MUCl cytoplasmic domain. That the MUCl 
cytoplasmic domain has the potential to interact with SH2 do- 
main containing proteins has been experimentally demon- 
strated by the binding of in-vitro tyrosine phosphorylated 
MUCl cytoplasmic domain to the src SH2 domain, the SH2 
domain derived from the N-terminal part of phospholipase C 
and to the GRB-2 protein (data not shown); no binding was 
observed to the SH2 domain derived from the C-terminal por- 
tion of p85 phosphatidyl inositol (PI) 3’ kinase. One should 
bear in mind that in-vitro tyrosine phosphorylated MUCl cyto- 
plasmic domain may not faithfully reflect he tyrosine phospho- 
rylation state of this protein within the cell; experiments inves- 
tigating the actual association of the MUCl protein with SH2 
domain second messenger proteins in vivo are presently being 
conducted. Nonetheless, the analyses described above do indi- 
cate that the tyrosine phosphorylated MUCl protein certainly 
has the potential to participate in such interactions. 
t 
Fig. 1 (continued). 
MUCl/REP or MUClN transfectants were labelled with radioactive carrier-free inorganic phosphate as described above and either treated with 
sodium vanadate and hydrogen Peroxide (lane 2, +) or not treated (lanel, -). Proteins immunoprecipitated with anticytoplasmic domain antibodies 
were visualized as above. Non-specifically immunoprecipitated proteins are indicated in (C) by the open arrow; the closed arrows indicate the 
specifically immunoprecipitated MUCl proteins. (E) (a) Phosphoamino acid analysis. The immunoprecipitated phosphorylated MUCl proteins (from 
lane 6 in (B)) were isolated from SDS-acrylamide (10%) gel and hydrolyzed in 6M HCl at 1lO’C for 1 h. Labelled phosphoaminoacids (with added 
unlabelled internal phosphoamino acid markers) were analyzed by thin-layer high voltage electrophoresis followed by Phosphorimager analysis. The 
position of migration of phosphoserine, phosphothreonine and phosphotyrosine are indicated by PS, PT and PY respectively and inorganic phosphate 
is shown by Pi. Phosphoamino acid analyses performed on the phosphorylated MUCl cleavage products (lanes 1 and 2 in (C)) and the phosphorylated 
MUClN proteins [lanes 1 and 2 in (D)] gave similar results (data not shown). (b) Reactivity of MUClN protein with anti-phosphotyrosine antibodies. 
MUClN ras 3T3 fibroblast transfectants were either treated with sodium vanadate and hydrogen peroxide (lane 2) or not treated (lane 1). Cell lysates 
were prepared and proteins immunoprecipita~ed with anticytoplasmic domain antibodies were resolved on SDS-polyacrylamide (10%) gels followed 
by immunoblotting and probing with antiphosphotyrosine antibodies (PY20 and PY69). The arrowed region indicates the tyrosine phosphorylated 
MUClN protein. (F) Scheme depicting the repeat array containing MUCl protein (upper molecule) and the novel MUClN protein (lower molecule) 
- the novel MUClN form is generated by an alternative splicing event that deletes the central tandem repeat array (compare upper and lower 
molecules). The location of tyrosine and cysteine residues are indicated above the rectangles by vertical ines and asterisks, respectively. Both MUCl 
forms contain a hydrophobic,N-terminal signal sequence (slashed box at left of figure) that is co-translationally cleaved (arrow at left of figure). This 
is followed by the tandem repeat array (upper molecule) that is illustrated by the block of closely spaced vertical ines. The highly hydrophobic 28 
amino acid stretch constituting the transmembrane domain (TM) is shown at the C-terminal end of both MUCl proteins, followed by the cytoplasmic 
domain (CYT). The region comprising the proteolytic cleavage site [15] of the repeat array containing MUCl protein (upper molecule) is indicated 
by the 2 vertical dotted arrows just N-terminal to the transmembrane domain. The regions recognized by the anti-cytoplasmic domain (anti-cyt) 
antibodies are indicated. 
134 
Considering that within the cell less than 1% of total protein 
phosphorylation occurs on tyrosine residues, and that when 
phosphorylated, phosphotyrosine residues play a pivotal role 
in signal transduction processes, both the extensive tyrosine 
phosphorylation of the MUCl proteins (Fig. 1) and the biased 
distribution of MUCl tyrosine containing sequences (Fig. 1) 
that can potentially interact with SH2 domain containing pro- 
teins, are especially significant findings. 
In an analogous fashion to a number of cytokine receptors 
[17-21,301, the MUCl proteins, as shown above, do not have 
intrinsic tyrosine kinase activity yet are phosphorylated on ty- 
rosine residues. As cytokine receptors are displayed on the cell 
surface as heteromeric protein complexes [17-211, we wished to 
investigate whether the MUCI proteins also form cell surface 
heteromeric complexes. Integrity of the MUCl extracellular 
domain is likely to be essential for binding of a putative ligand, 
and these studies therefore concentrated on the MUClN 
isoform. Addition to MUClN expressing transfectants of a 
crosslinking agent that does not penetrate the cell membrane 
lead to a substantial decline in the level of the mature cell- 
surface located 42-45 kDa MUClN protein and concomi- 
tantly to the appearance of a new 60 kDa band (Fig. 2, lanes 
3 and 6), thereby demonstrating that the MUClN protein is 
complexed with other cell-surface located molecules. Notably, 
the cytoplasmically located precursor 33 kDa MUClN protein 
was not affected by treatment with the crosslinking agent (Fig. 
2, lanes 3 and 6), indicating that complex formation involved 
only the mature cell surface located MUCIN protein. It should 
be noted that in subsequent cross-linking experiments the 60 
kDa MUClN complex was consistently observed although the 
levels of the cell-surface located 42-45 kDa MUClN protein 
were somewhat higher than those observed in the experiment 
described above - the reason for this variability is unknown. 
Furthermore, gel analysis of the MUClN protein from cells 
not treated with the crosslinking agent showed, under non- 
reducing conditions and in the presence of iodoacetamide, a 
prominent 60 kDa band (Fig. 2, lane 5) that migrated to an 
identical position as the cross-linked 60 kDa MUClN protein. 
This band was not observed under reducing conditions (com- 
pare Fig. 2, lanes 2 and 5), indicating that MUClN complex 
formation is likely to be mediated, at least in part, by cysteine 
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residues that form reducible disuhide bridges. The recently 
described interferon o//3 cytokine receptor [31] has also been 
shown to form disulfide-linked dimer complexes - the cysteine 
residues within this cytokine receptor that are responsible for 
dimerization have, however, not been identified. The MUCl 
protein contains only 3 cysteines - one cysteine residue appears 
within the transmembrane domain and the remaining two are 
located in a Cys-Gm-Cys tripeptide just C-terminal to the trans- 
membrane domain (see Fig. 1F for location of cysteine residues 
within the complete MUCl protein). An identical cytoplasmi- 
tally located Cys-Ghr-Cys tripeptide sequence has been previ- 
ously shown to mediate complex formation of the cell surface 
CD4 molecule [32], and we thus investigated whether the 
MUCl Cys-Ghr-Cys sequence may play a similar role in 
MUClN complex formation. Transfectants were generated 
that expressed a mutant form of MUClN in which the Cys- 
Gln-Cys sequence had been mutated to Gly-Gln-Gly. These 
mutants expressed the 42-45 kDa MUClN protein that mi- 
grated to an identical position as the wild type MUClN pro- 
tein (Fig. 2, lane 1). However, in marked contrast to the wild 
type MUClN protein, the mutant MUClN protein did not 
form, under non-reducing conditions, the 60 kDa complex (Fig. 
2, lane 4). Additional experiments involving treatment of the 
mutant MUClN transfectant with the crosslinking agent dem- 
onstrated only very low levels of the MUClN 60 kDa complex 
(data not shown). This indicates that formation of the MUCl N 
60 kDa complex is primarily mediated by the two cysteine 
residues present in the Cys-Gln-Cys tripeptide which form di- 
sulfide bridges, and that non-covalent protein-protein interac- 
tions may only play a minor role in complex formation. Al- 
though the molecular mass of the 60 kDa complex suggests that 
it is a disuhide linked heterodimer, we cannot rule out at this 
stage the possibility of an anomalously migrating homodimer 
or even a complex of more than 2 protein molecules. 
It is thereby demonstrated that, as in the case of cytokine 
receptors, the MUClN protein is also presented at the cell 
surface complexed to other membrane proteins. Furthermore, 
the MUCl amino acid sequence reveals striking similarities to 
cytokine receptor sequences that are known to participate in 
ligand binding [33-361 (Fig. 3). For example, when considering 
only identical amino acid residues and Ser-Thr substitutions the 
huGHR II n YELII/mII:EV NE WKMMDP I 
m/3 IL-3R ti ¤&&W~HKK Sam WKD 
huf! c 6% n FE IIII 
hu IL7-R n n n AYR~ElDmNKW 
Fig. 3. Sequence alignment of residues in the MUCl extracelhilar domain with the predicted ligand binding domains of cytokine receptors. The 
MUClN extracellular domain amino acid sequence starting at amino acid number 114 [8] is compared to the.predicted loop between the C-terminal 
B and C strands in the proposed double /?-barrel structural models of the human interleukin 7 receptor (huIL-7R), /3 chain mouse IL-3 receptor 
(@IL-3R), common fi subunit of human GM-CSF (granulocyte-macrophage colony stimulating factor), IL-3 and IL-5 receptors (lu$cR) and the 
human growth hormone receptor (huGHR). Identical amino acids are heavily shaded and conservatively substituted amino acids are lightly shaded. 
Note that the His-Asp (HD) dipeptide sequence that is proximal to the N-terminal of both the IL-7 receptor and MUCl sequences appears as Asp-His 
(DH) both in the B chain mouse IL-3 receptor (@IL-3R) and in the common /? subunit of human GM-CSF (granulocyte-macrophage colony 
stimulating factor), IL-3 and IL-5 receptors (h$cR), and the Ghr-Phe (QF) dipeptide that is present in the MUCl sequence appears in the/l chain 
mouse IL-3 receptor (m IL-3R) as Phe-Gln (FQ). 
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human IL-7 receptor shows 44% homology with MUCl ex- 
tracellular domain sequences over a stretch of 27 amino acids 
that span the ligand binding site- if one also includes in this 
homology comparison valine to leucine and valine to methion- 
ine substitutions, the extent of homology increases to 55%. 
Significantly this homology maps in close proximity to the 
region where proteolytic cleavage occurs in the MUCl/REP 
protein, suggesting that integrity of this site in the MUClN 
protein may be of prime importance for both ligand binding 
and signal transmission and that different mechanisms may be 
responsible for activation of the two MUCl isoforms. The 
MUClN protein, however, contains neither the conserved ex- 
tracellular domain cysteine residues nor the Trp-Ser-Xxx-Trp- 
&, motif that are characteristic of many cytokz receptors 
[20]- it is notable that this latter motif appears in the human 
growth hormone receptor as Tyr-Gly-Glu-Phe-Ser and not as 
the canonical WEXWS. It is therefore interest&-that a Phe- 
&-Xxx-Xxx-& motif (Phe-Ser-Ala-Gln-w does appear in 
the MUCl sequence just N-terminal to the transmembrane 
domain, at an identical location to the WSXWS motif, seen in 
cytokine receptors. 
Taken together, these data demonstrate that the MUCl pro- 
teins participate in signal transduction and that the MUCIN 
protein may act as a cytokine receptor-like molecule. 
It has been shown here for the first time that the MUCl 
proteins are extensively phosphorylated, that phosphorylation 
occurs on tyrosine residues and that following phosphorylation 
the MUCl proteins may potentially interact with SH2 domain 
containing proteins and thereby initiate a signal transduction 
cascade. As with cytokine receptors [17], the MUClN protein 
does not harbor intrinsic tyrosine kinase activity yet is tyrosine 
phosphorylated, and participates in a cell-surface heteromeric 
complex - furthermore, the MUClN protein demonstrates 
sequence similarity with sequences present in cytokine recep- 
tors that are known to be involved in ligand binding. Indeed, 
the striking enhancement of MUCl phosphorylation (Fig. 
lC,D) elicited by the tyrosine phosphatase inhibitors suggests 
the existence of regulatory mechanisms, such as ligand binding 
to the MUCl extracellular domains or/and cellular redox po- 
tential changes [371 that may control MUCl tyrosine phospho- 
rylation levels by activating cytoplasmic kinases which subse- 
quently transphosphorylate the MUCl proteins. These features 
suggest hat the MUClN protein may act in a similar fashion 
to cytokine receptors and that following binding of an as yet 
unidentified ligand, undergo transphosphorylation mediated 
by cytoplasmic tyrosine kinases such as the Janus kinases 
[ 17,301. 
Notwithstanding the fact that the two MUCl isoforms have 
identical cytoplasmic domains, are phosphorylated on tyrosine 
residues and are both likely to participate in signal transduction 
processes, the difference in their extracellular domain structure 
and the cleavage of the MUCl/REP form as opposed to the 
integrity of MUClN all argue against identical functions as 
well as activating mechanisms for the two isoforms. 
We have previously shown that both the MUCl/REP and 
MUClN proteins are highly expressed in human breast cancer 
tissue [8]. The elucidation of mechanisms that activate the cell- 
surface located MUCl proteins, shown here to be intimate- 
ly linked to signal transduction and oncogenetic processes, 
may lead to new modalities for the treatment of human breast 
cancer. 
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